Aging Researcher on the Influence of Genetics and Weight Loss Injections

Cologne aging researcher Björn Schumacher recently discussed the role of genes and new substances in aging research in an interview. According to Schumacher, our genes influence about 30 percent of life expectancy. The remaining 70 percent are determined by environmental factors, lifestyle, and possibly also by new therapeutic approaches. Schumacher emphasizes that research on weight loss injections, which have gained popularity in recent years, could offer promising approaches to slowing down the aging process. These injections contain substances originally developed for the treatment of obesity but may also show positive effects on cellular aging.

A central aspect of the research is the investigation of how these substances affect metabolic processes in the body. Schumacher explains that by modulating metabolism, it may also be possible to slow down aging processes in cells. This could lead to an increase in quality of life in old age. Researchers are also examining the extent to which these substances can promote cell regeneration. Initial studies show that certain substances contained in weight loss injections support the cells' ability to self-repair.

This could contribute to preventing age-related diseases in the long term. Another important point is the interaction between genetic factors and the substances. Schumacher emphasizes that not all individuals respond equally to these therapies. Genetic variations could influence the effectiveness of weight loss injections, highlighting the need for individualized treatment approaches. However, research is still in its early stages.

Current studies focus on understanding the exact mechanisms through which these substances work. Schumacher points out that it is important to investigate the long-term effects on health before these therapies can be widely implemented. The results of this research could have far-reaching implications for geriatric medicine. Schumacher sees potential in such therapies not only to slow down aging but also to significantly improve quality of life in old age. This could be particularly relevant for the aging population. The next steps in the research include clinical trials that will further evaluate the safety and efficacy of weight loss injections. Schumacher emphasizes that researchers aim to present initial results from these studies by 2028.